Availability and role of clinical pharmacists in ambulatory neuro-oncology.

Autor: Patel MP; Department of Pharmacy, Duke University Medical Center, Durham, North Carolina, USA., Lipp ES; Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina, USA., Miller ES; Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina, USA., Healy PN; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, USA., Herndon JE 2nd; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, USA., Peters KB; Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina, USA.
Jazyk: angličtina
Zdroj: Neuro-oncology practice [Neurooncol Pract] 2021 Oct 22; Vol. 9 (1), pp. 18-23. Date of Electronic Publication: 2021 Oct 22 (Print Publication: 2022).
DOI: 10.1093/nop/npab060
Abstrakt: Background: Outpatient clinics treating neuro-oncology patients are becoming more multidisciplinary. Utilization of all team members is critical for the holistic care of these complex patients. Specifically, the role of clinical pharmacist (CP) in the ambulatory clinic remains undefined and will likely evolve as more therapeutics are developed for CNS malignancies. We queried the Society for Neuro-Oncology (SNO) membership about the availability of a CP in their ambulatory setting and, if present, the role of that CP.
Methods: In an IRB-exempt study, we surveyed the SNO community and analyzed responses to queries about CPs in the ambulatory setting.
Results: Of the 65 SNO members who responded, 52 were clinical members. Of these 52 clinicians, the majority were physicians (88.5%, n = 46). Of these physicians, most were in academic practices (93.5%, n = 43). Over half of the 52 clinical respondents (51.9%, n = 27) reported that they saw ≥30 primary brain tumor patients per month, thus typifying busy clinics. Despite having busy clinics, only 12 (28.6%) of 42 providers with access to a CP reported that their CP was solely dedicated to neuro-oncology patients. For the respondents who had access to a CP, only ~two-thirds of those CPs had direct patient interaction. The top 3 roles of the CP included medication review, chemotherapy dosing/modifications, and practice guideline development; none of which involve direct patient interaction.
Conclusions: We found that while our surveyed population of SNO clinical members have demanding outpatient practices, most do not have the support or expertise of dedicated neuro-oncology CPs.
(© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje